Epigenomics has licensed the SEPT9 biomarker and certain DNA methylation technologies to Quest Diagnostics and ARUP Laboratories in the US, as well as Warnex Laboratories in Canada.
•
SEPT9 - Measurement in blood for detection of colon cancer.
•
Epi proColon - a test to measure the methylation status of the SEPT9 promoter in plasma as an aid in early detection of colon cancer.